✦ LIBER ✦

Clinical pharmacology of bruceantin by radioimmunoassay

✍ Scribed by K. L. L. Fong; D. H. W. Ho; R. S. Benjamin; N. S. Brown; A. Bedikian; B. S. Yap; C. L. Wiseman; W. Kramer; G. P. Bodey

Publisher: Springer
Year: 1982
Tongue: English
Weight: 399 KB
Volume: 9
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00257747

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bleomycin clinical pharmacology by radio

Bleomycin clinical pharmacology by radioimmunoassay

✍ Stephen W. Hall; James E. Strong; Alan Broughton; Marsha L. Frazier; Robert S. B 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 366 KB

Bleomycin pharmacokinetics were studied by radioimmunoassay in 11 patients who received 7-30 U intravenously (IV) and eight patients who received 4-30 U subcutaneously (SC). For patients who received IV bleomycin plasma disappearance was biphasic, with a mean initial half-life of 0.26 h and a termin

Radioimmunoassay for the detection and q

Radioimmunoassay for the detection and quantitation of bruceantin

✍ Kei-Lai L. Fong; Dah Hsi W. Ho; Carol J.K. Carter; Nita S. Brown; Robert S. Benj 📂 Article 📅 1980 🏛 Elsevier Science 🌐 English ⚖ 475 KB

A radioimmunoassay for a new anticancer drug, bruceantin, has been developed using [3H]acetylbruceantin and antibody induced by immunizing rabbits with succinylbruceantinbovine serum albumin conjugates. [3H]Acetylbruceantin was synthesized by reacting bruceantin with [3H]acetyl anhydride. The assay

Clinical pharmacology of bleomycin follo

Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay

✍ Alan Broughton; James E. Strong; Paul Y. Holoye; Carlos W. M. Bedrossian 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 513 KB

The clinical pharmacology of bleomycin administered by continuous intravenous infusion over a 4 to 5 day period was examined in nine patients. Patients receiving 30 units per day attained an average steady state plasma level of 145.8 (f 43.l)ng/ml bleomycin. Elimination of bleomycin was initially de

Pharmacology and clinical pharmacology o

Pharmacology and clinical pharmacology of organic nitrates

✍ H. Grobecker 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 469 KB

Clinical pharmacology of methotrexate

✍ Bertino, J. R. 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 746 KB

## Abstract Methotrexate (MTX), a potent folate antagonist by virtue of its ability to inhibit the enzyme dihydrofolate reductase [1], continues to be a useful cancer chemotherapeutic agent [2]. Information not only on its mechanism of action, but also its pharmacology has led to improved dosage sc

Clinical pharmacology of carvedilol

✍ Tomlinson, B. ;Prichard, B.N.C. ;Graham, B.R. ;Walden, R.J. 📂 Article 📅 1992 🏛 Springer-Verlag 🌐 English ⚖ 922 KB

Animal work has shown that carvedilol is a nonselective beta-blocking drug. It has a vasodilator action from alpha-receptor blockade, but there is evidence that it has further action to relax smooth muscle, possibly from calcium channel antagonism. Carvedilol is lipid soluble and 25% bioavailable, a